Seroprevalence of IgG and Subclasses against the Nucleocapsid of SARS-CoV-2 in Health Workers.
COVID-19
IgG
N protein
SARS-CoV-2
antibodies
health workers
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
13 04 2023
13 04 2023
Historique:
received:
28
02
2023
revised:
28
03
2023
accepted:
03
04
2023
medline:
1
5
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
The nucleocapsid protein of SARS-CoV-2 participates in viral replication, transcription, and assembly. Antibodies against this protein have been proposed for the epidemiological analysis of the seroprevalence of COVID-19 associated with natural infection by SARS-CoV-2. Health workers were one of the most exposed populations, and some had an asymptomatic form of the disease, so detecting IgG antibodies and subclasses against the N protein can help to reclassify their epidemiological status and obtain information about the effector mechanisms associated with viral elimination. In this study, we analyzed 253 serum samples collected in 2021 and derived from health workers, and evaluated the presence of total IgG and subclasses against the N protein of SARS-CoV-2 by indirect ELISA. From the analyzed samples, 42.69% were positive to anti-N IgG antibodies. A correlation between COVID-19 asymptomatic infection and IgG antibodies was observed ( This work provides evidence about the high seroprevalence of total IgG and subclasses of anti-N and their relations with the asymptomatic infection of SARS-CoV-2 and related symptoms.
Sections du résumé
BACKGROUND
The nucleocapsid protein of SARS-CoV-2 participates in viral replication, transcription, and assembly. Antibodies against this protein have been proposed for the epidemiological analysis of the seroprevalence of COVID-19 associated with natural infection by SARS-CoV-2. Health workers were one of the most exposed populations, and some had an asymptomatic form of the disease, so detecting IgG antibodies and subclasses against the N protein can help to reclassify their epidemiological status and obtain information about the effector mechanisms associated with viral elimination.
METHODS
In this study, we analyzed 253 serum samples collected in 2021 and derived from health workers, and evaluated the presence of total IgG and subclasses against the N protein of SARS-CoV-2 by indirect ELISA.
RESULTS
From the analyzed samples, 42.69% were positive to anti-N IgG antibodies. A correlation between COVID-19 asymptomatic infection and IgG antibodies was observed (
CONCLUSIONS
This work provides evidence about the high seroprevalence of total IgG and subclasses of anti-N and their relations with the asymptomatic infection of SARS-CoV-2 and related symptoms.
Identifiants
pubmed: 37112935
pii: v15040955
doi: 10.3390/v15040955
pmc: PMC10141201
pii:
doi:
Substances chimiques
Immunoglobulin G
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Transl Immunology. 2021 Mar 14;10(3):e1261
pubmed: 33747511
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
Emerg Microbes Infect. 2020 Dec;9(1):221-236
pubmed: 31987001
Antibodies (Basel). 2019 Apr 25;8(2):
pubmed: 31544836
Cell. 2020 May 14;181(4):914-921.e10
pubmed: 32330414
Viruses. 2014 Aug 07;6(8):2991-3018
pubmed: 25105276
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
J Infect Dis. 2021 Jan 4;223(1):62-71
pubmed: 33175145
Nat Commun. 2011 Dec 20;2:599
pubmed: 22186895
Sci China Life Sci. 2022 Feb;65(2):280-294
pubmed: 34387838
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S41-52
pubmed: 20176268
Allergy. 2020 Nov;75(11):2829-2845
pubmed: 32496587
Immunol Invest. 2021 May;50(4):427-444
pubmed: 32522062
Front Immunol. 2021 Mar 04;12:632814
pubmed: 33763078
Front Immunol. 2021 Aug 19;12:723585
pubmed: 34489974
PLoS Med. 2021 Dec 10;18(12):e1003877
pubmed: 34890407
Vaccines (Basel). 2022 Jan 30;10(2):
pubmed: 35214678
Clin Chem Lab Med. 2020 Aug 26;58(12):2107-2111
pubmed: 32845861
Infect Control Hosp Epidemiol. 2022 Sep;43(9):1207-1215
pubmed: 34369331
Lung. 2020 Dec;198(6):867-877
pubmed: 33170317
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2025-e2034
pubmed: 33524125
Perioper Med (Lond). 2021 Mar 2;10(1):7
pubmed: 33648573
Front Immunol. 2013 Aug 09;4:235
pubmed: 23950757
Occup Environ Med. 2020 Dec 9;:
pubmed: 33298533
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
Lancet. 2022 Apr 23;399(10335):1618-1624
pubmed: 35397851
PLoS One. 2022 Aug 15;17(8):e0273097
pubmed: 35969583
J Basic Microbiol. 2021 Mar;61(3):180-202
pubmed: 33460172
J Biol Chem. 2020 Sep 11;295(37):12910-12934
pubmed: 32661197
BMC Infect Dis. 2022 Sep 3;22(1):721
pubmed: 36057544
Cell Rep Med. 2021 Jul 20;2(7):100329
pubmed: 34151306
J Med Virol. 2022 Jan;94(1):380-383
pubmed: 34403142
Viruses. 2022 Sep 14;14(9):
pubmed: 36146847
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330